List view / Grid view
9 December 2014 | By Roche
Presentations include data on Roche’s broad portfolio of hematology medicines as well as emerging investigational agents including ACE910 (RG6013) in hemophilia A...
9 December 2014 | By Roche
Victory for Scottish NHS patients as SMC accepts Gazyvaro™ (obinutuzumab) for treatment of most common adult leukaemia...
9 December 2014 | By Roche
cobas HIV-1 and HCV assays offer unparalleled performance on cobas 6800/8800 Systems...
2 December 2014 | By Roche
Victory for patients as NICE accepts Gazyvaro™ (obinutuzumab) for treatment of most common adult leukaemia1...
2 December 2014 | By Roche
Roche announced the acquisition of Ariosa Diagnostics, Inc. (Ariosa), a privately-held company based in San Jose, California, USA...
25 November 2014 | By Roche
Roche is increasing the payroll for its workforce of over 13,000 in Switzerland by 1.4 percent with effect from 1 April 2015...
17 November 2014 | By Roche
Avastin plus chemotherapy reduced the risk of the disease worsening by 62 percent compared to chemotherapy alone in a Phase III study...
14 November 2014 | By Roche
The cobas Strep A test is the first molecular point of care test to provide a result in 15 minutes for this common infection...
5 November 2014 | By Roche
Addressing Asia Pacific’s growing demand for diagnostics...
27 October 2014 | By Roche
Roche announced that Esbriet® (pirfenidone) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for an update to its European prescribing information, strengthening the efficacy claims and supporting the well-established safety profile based on the additional data from the phase III ASCEND trial...
22 October 2014 | By Roche
Investments of 3 billion Swiss francs in modern research infrastructure, attractive workplaces and sustainable site development...
16 October 2014 | By Roche
Roche announce Q3 2014 results...
16 October 2014 | By Roche
Roche announced that the U.S. Food and Drug Administration has approved Esbriet (pirfenidone) as a treatment for idiopathic pulmonary fibrosis in the United States...
9 October 2014 | By Roche
Roche announced that the U.S. Food and Drug Administration has accepted to file the company's supplemental Biologics License Application and granted Priority Review of Lucentis (ranibizumab injection) for the treatment of diabetic retinopathy, an eye disease that impacts nearly 7.7 million Americans...
30 September 2014 | By Roche
Roche and InterMune, Inc. announced that Roche’s wholly owned subsidiary Klee Acquisition Corporation has accepted for payment all shares validly tendered pursuant to its tender offer for all outstanding shares of common stock of InterMune, Inc. at USD 74.00 per share in cash...
